A Dose-finding Study for SPM 962 in Advanced Parkinson's Disease Patients
Status:
Completed
Trial end date:
2008-04-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to investigate efficacy and safety of SPM 962 in
advanced Parkinson's Disease (PD) patients in a multi-center, placebo-controlled study
following once-daily multiple transdermal doses of SPM 962 within a range of 4.5 to 36.0 mg
(12 weeks of dose titration/maintenance period). Recommended maintenance dose range is also
to be investigated with distribution of the maintenance dose and accumulated response rate of
efficacy.